Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Types of histiocytosis and their treatment strategies

Roei Mazor • 10 Jun 2022
EHA 2022
Histiocytosis Langerhans Cell Histiocytosis Non-Malignant Rare Diseases Checkpoint inhibitors

Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, shares some insights into Langerhans cell histiocytosis (LCH) and explains how different subtypes of histiocytosis differ from one another by various factors including the driver oncogene, the clinical presentation, and by the capacity to diverge and to generate a polyclonal phenotype. The different treatment strategies for LCH and malignant histiocytosis are described. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Roei Mazor

2:13
An insight into Langerhans cell histiocytosis and advances in treatment approaches
Roei Mazor • 10 Jun 2022
1:37
Case study update: alpelisib for the treatment of PI3K-driven Langerhans cell histiocytosis
Roei Mazor • 10 Jun 2022

Related Videos

2:27
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
Farrukh Shah • 30 Apr 2024
1:06
The importance of shared-decision making when treating infants with hemophilia
Jayashree Motwani • 28 Apr 2024
2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
2:40
The safety & efficacy of emicizumab in patients under 18 months with hemophilia A
Eman Hassan • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals